Holen Sie sich die Stockscreener-App
1.83
2.23%
0.04
Handel nachbörslich:
1.88
0.05
+2.73%
Schlusskurs vom Vortag:
$1.79
Offen:
$1.77
24-Stunden-Volumen:
5.72M
Relative Volume:
2.86
Marktkapitalisierung:
$399.27M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-3.5192
EPS:
-0.52
Netto-Cashflow:
$-23.38M
1W Leistung:
-1.08%
1M Leistung:
+2.23%
6M Leistung:
+94.68%
1J Leistung:
+52.50%
1-Tages-Spanne:
$1.75
$1.87
1-Wochen-Bereich:
$1.74
$1.90
52-Wochen-Spanne:
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.83 | 399.27M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
404,718 Shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Acquired by Wellington Management Group LLP - MarketBeat
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years - Yahoo Finance
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Eastern Progress Online
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - The Eastern Progress Online
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Hold Rating - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - Kilgore News Herald
Akebia Therapeutics to Present at Upcoming Investor Conferences - The Eastern Progress Online
New Strong Sell Stocks for December 5th - Yahoo Finance
Akebia Therapeutics (FRA:AX9) EBITDA : €4.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Longview News-Journal
Akebia Therapeutics Awards 121,000 Stock Options to New Employees in Retention Push - StockTitan
Biotech Alert: Searches spiking for these stocks today - TipRanks
New Strong Sell Stocks for November 27th - Yahoo Finance
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Vadadustat Alternative Dosing Study Results Published in the Ame - GuruFocus.com
AKBA (Akebia Therapeutics) Future 3-5Y Total Revenue Growth Rate : 9.95 (As of Nov. 23, 2024) - GuruFocus.com
Akebia Therapeutics to Report Third Quarter 2024 Financial Resul - GuruFocus.com
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply C - GuruFocus.com
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - GuruFocus.com
Q3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA) - Seeking Alpha
Akebia's FDA-Approved Vafseo Shows Promise in Key Dialysis Trial Results | AKBA Stock News - StockTitan
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - Longview News-Journal
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance
Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Akebia Therapeutics: Q3 Earnings Snapshot - CT Insider
Akebia Therapeutics Prepares for Vafseo Launch - TipRanks
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akebia Therapeutics Inc-Aktie (AKBA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dahan Michel | SVP, Chief Operating Officer |
May 13 '24 |
Sale |
1.26 |
34,840 |
43,898 |
672,092 |
| Dahan Michel | SVP, Chief Operating Officer |
Feb 29 '24 |
Sale |
1.58 |
8,661 |
13,684 |
706,932 |
| Hadas Nicole R. | SVP, Chief Legal Officer |
Feb 29 '24 |
Sale |
1.58 |
5,974 |
9,439 |
663,259 |
| Butler John P. | CEO and President |
Feb 29 '24 |
Sale |
1.58 |
46,570 |
73,581 |
2,044,580 |
| Burke Steven Keith | SVP, Chief Medical Officer |
Feb 29 '24 |
Sale |
1.58 |
7,169 |
11,327 |
695,840 |
| Hadas Nicole R. | SVP, Chief Legal Officer |
Feb 27 '24 |
Sale |
1.52 |
7,411 |
11,265 |
669,233 |
| Dahan Michel | SVP, Chief Operating Officer |
Feb 27 '24 |
Sale |
1.52 |
10,744 |
16,331 |
715,593 |
| Burke Steven Keith | SVP, Chief Medical Officer |
Feb 27 '24 |
Sale |
1.52 |
8,367 |
12,718 |
703,009 |
| Butler John P. | CEO and President |
Feb 27 '24 |
Sale |
1.52 |
37,733 |
57,354 |
2,091,150 |
| Butler John P. | CEO and President |
Feb 01 '24 |
Sale |
1.68 |
46,489 |
78,102 |
2,128,883 |
1.61%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):